Rachelle S. Jacques's most recent trade in uniQure N.V. was a trade of 2,112 Ordinary Shares done at an average price of $14.4 . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| uniQure N.V. | Rachelle S. Jacques | Director | Sale of securities on an exchange or to another person at price $ 14.45 per share. | 20 Jun 2025 | 2,112 | 28,346 (0%) | 0% | 14.4 | 30,518 | Ordinary Shares |
| uniQure N.V. | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 15,630 | 15,630 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 7,970 | 30,458 (0%) | 0% | 0 | Ordinary Shares | |
| Corbus Pharmaceuticals Hol... | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 16,000 | 16,000 | - | - | Stock options (right to buy) | |
| Corbus Pharmaceuticals Hol... | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 4,800 | 7,583 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| uniQure N.V. | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 15,840 | 15,840 | - | - | Stock Option (Right to Buy) | |
| uniQure N.V. | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 8,080 | 22,488 (0%) | 0% | 0 | Ordinary Shares | |
| uniQure N.V. | Rachelle S. Jacques | Director | Sale of securities on an exchange or to another person at price $ 5.14 per share. | 13 Jun 2024 | 2,221 | 14,408 (0%) | 0% | 5.1 | 11,416 | Ordinary Shares |
| Corbus Pharmaceuticals Hol... | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals Hol... | Rachelle S. Jacques | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | |
| Akari Therapeutics Plc - ADR | Rachelle S. Jacques | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2024 | 479,569,892 | 1,018,027,792 (66%) | 31% | 0 | Ordinary Shares, par value $0.0001 per share |